The shares in Oncoinvent ASA will from today, 23 September 2026, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 22 September 2026.
This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com